EA201591480A1 - Способы лечения дискинезии и сопутствующих расстройств - Google Patents

Способы лечения дискинезии и сопутствующих расстройств

Info

Publication number
EA201591480A1
EA201591480A1 EA201591480A EA201591480A EA201591480A1 EA 201591480 A1 EA201591480 A1 EA 201591480A1 EA 201591480 A EA201591480 A EA 201591480A EA 201591480 A EA201591480 A EA 201591480A EA 201591480 A1 EA201591480 A1 EA 201591480A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
related disorders
treating
disorders
diskinesia
Prior art date
Application number
EA201591480A
Other languages
English (en)
Other versions
EA032064B1 (ru
Inventor
Джон Чаллелла
Джон Грюнер
Эндрю Г. Реом
Майкл С. Сапорито
Original Assignee
Мелиор Дискавери, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мелиор Дискавери, Инк. filed Critical Мелиор Дискавери, Инк.
Publication of EA201591480A1 publication Critical patent/EA201591480A1/ru
Publication of EA032064B1 publication Critical patent/EA032064B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

В настоящем изобретении раскрыты соединения и их фармацевтически приемлемые соли и композиции и составы, содержащие их, которые пригодны для способов лечения дискинезии или сопутствующих расстройств, и способы лечения дискинезии или сопутствующих расстройств. В настоящем изобретении описаны соединения, композиции и составы, содержащие терапевтически или профилактически активные вещества или их фармацевтически приемлемые соли для лечения и/или предотвращения дискинезий или других расстройств, и способы лечения дискинезии и других расстройств.
EA201591480A 2013-03-15 2014-03-14 Способ лечения леводопа-индуцированной дискинезии с применением сиднокарба EA032064B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786714P 2013-03-15 2013-03-15
PCT/US2014/029827 WO2014145126A2 (en) 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders

Publications (2)

Publication Number Publication Date
EA201591480A1 true EA201591480A1 (ru) 2016-03-31
EA032064B1 EA032064B1 (ru) 2019-04-30

Family

ID=51538415

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591480A EA032064B1 (ru) 2013-03-15 2014-03-14 Способ лечения леводопа-индуцированной дискинезии с применением сиднокарба

Country Status (15)

Country Link
US (5) US9051312B2 (ru)
EP (1) EP2970160B1 (ru)
JP (1) JP6605447B2 (ru)
KR (3) KR20240004497A (ru)
CN (1) CN105209445B (ru)
AU (1) AU2014233334B2 (ru)
BR (1) BR112015023116A2 (ru)
CA (1) CA2904539C (ru)
EA (1) EA032064B1 (ru)
HK (1) HK1220453A1 (ru)
IL (1) IL241114B (ru)
MX (1) MX2015013151A (ru)
SG (2) SG10201707560TA (ru)
WO (1) WO2014145126A2 (ru)
ZA (1) ZA201506705B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853791B2 (ja) * 2015-05-26 2021-03-31 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー パーキンソン病及び関連する障害の治療における使用のための組成物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4282862A1 (en) * 2022-05-25 2023-11-29 Irbm S.P.A. Flavivirus inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1496056A (fr) * 1964-06-08 1967-09-29 Takeda Chemical Industries Ltd Nouveaux composés chimiques du type sydnonimine
GB1262830A (en) 1970-06-10 1972-02-09 Vni Khim Farmatsevtichesky I I Novel sydnonimine derivative
CA1097659A (en) * 1976-11-25 1981-03-17 Roald A. Altshuler Sydnonimine n-acylderivatives and method for preparing same
US4277609A (en) * 1979-08-31 1981-07-07 American Home Products Corporation Sydnone imines
US4446322A (en) * 1980-07-29 1984-05-01 American Home Products Corporation Hydroxyl protected 3-(2-hydroxy-2-phenylethyl)-N-[(phenylamino)carbonyl]sydnone imine intermediates
US4324897A (en) * 1980-10-02 1982-04-13 American Home Products Corporation 1,2,3 Oxadiazolium salts
DE3921796A1 (de) * 1989-07-03 1991-01-17 Cassella Ag Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
AU3632393A (en) * 1992-03-24 1993-10-21 Cassella Aktiengesellschaft Use of sydnonimines to treat erectile dysfunction
KR20040111324A (ko) * 2002-05-30 2004-12-31 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 트리사이클릭 파이라졸로트리아졸로피리미딘 링 구조를지닌 약제학적 활성화합물 및 사용 방법
US8691853B2 (en) * 2007-03-14 2014-04-08 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
WO2008112968A1 (en) * 2007-03-14 2008-09-18 Caliper Life Sciences, Inc. Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
CN102791134B (zh) * 2009-12-04 2015-04-22 魄金莱默有限公司 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders

Also Published As

Publication number Publication date
HK1220453A1 (zh) 2017-05-05
CA2904539C (en) 2022-05-03
US9051312B2 (en) 2015-06-09
US11351169B2 (en) 2022-06-07
CN105209445B (zh) 2018-01-23
US20150231116A1 (en) 2015-08-20
AU2014233334A1 (en) 2015-10-08
WO2014145126A2 (en) 2014-09-18
IL241114A0 (en) 2015-11-30
WO2014145126A3 (en) 2014-12-18
SG10201707560TA (en) 2017-11-29
EP2970160A2 (en) 2016-01-20
EP2970160A4 (en) 2017-01-25
US9402830B2 (en) 2016-08-02
NZ712291A (en) 2020-10-30
US20220331320A1 (en) 2022-10-20
US10188651B2 (en) 2019-01-29
KR20240004497A (ko) 2024-01-11
KR20210113429A (ko) 2021-09-15
IL241114B (en) 2019-07-31
JP2016514698A (ja) 2016-05-23
ZA201506705B (en) 2017-09-27
US20190328736A1 (en) 2019-10-31
AU2014233334B2 (en) 2018-07-19
US20140371231A1 (en) 2014-12-18
CA2904539A1 (en) 2014-09-18
CN105209445A (zh) 2015-12-30
JP6605447B2 (ja) 2019-11-13
EA032064B1 (ru) 2019-04-30
EP2970160B1 (en) 2020-11-11
US20170042894A1 (en) 2017-02-16
BR112015023116A2 (pt) 2017-07-18
KR102301073B1 (ko) 2021-09-10
SG11201507257RA (en) 2015-10-29
KR20150132391A (ko) 2015-11-25
MX2015013151A (es) 2016-04-11

Similar Documents

Publication Publication Date Title
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
PH12015502028A1 (en) Ido inhibitors
EA201591509A1 (ru) Ингибиторы cdc7
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
EA201690027A1 (ru) Ингибиторы ido
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.